Developing Oncolytic Viruses for the Treatment of Cervical Cancer

Cervical cancer represents one of the most important malignancies among women worldwide. Current therapeutic approaches for cervical cancer are reported not only to be inadequate for metastatic cervical cancer, but are also considered as cytotoxic for several patients leading to serious side effects...

Full description

Saved in:
Bibliographic Details
Published in:Cells (Basel, Switzerland) Switzerland), 2023-07, Vol.12 (14), p.1838
Main Authors: Kalafati, Eleni, Drakopoulou, Ekati, Anagnou, Nicholas P, Pappa, Kalliopi I
Format: Article
Language:English
Subjects:
Adenoviruses
Angiogenesis
cancer immunotherapy
Cancer therapies
Care and treatment
Cell cycle
Cell growth
Cervical cancer
Clinical trials
Cytotoxicity
FDA approval
Human papillomavirus
Immune system
Immunotherapy
innate immunity
Malignancy
Medical prognosis
Medical screening
Metastases
Metastasis
Oncolysis
oncolytic viruses
Prevention
Proteins
Quality of life
Review
Tumors
viral vectors
virotherapy
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cervical cancer represents one of the most important malignancies among women worldwide. Current therapeutic approaches for cervical cancer are reported not only to be inadequate for metastatic cervical cancer, but are also considered as cytotoxic for several patients leading to serious side effects, which can have negative implications on the quality of life of women. Therefore, there is an urgent need for the development of innovative and effective treatment options. Oncolytic viruses can eventually become effective biological agents, since they preferentially infect and kill cancer cells, while leaving the normal tissue unaffected. Moreover, they are also able to leverage the host immune system response to limit tumor growth. This review aims to systematically describe and discuss the different types of oncolytic viruses generated for targeting cervical cancer cells, as well as the outcome of the combination of virotherapy with conventional therapies. Although many preclinical studies have evaluated the therapeutic efficacy of oncolytic viruses in cervical cancer, the number of clinical trials so far is limited, while their oncolytic properties are currently being tested in clinical trials for the treatment of other malignancies.
ISSN:2073-4409
2073-4409
DOI:10.3390/cells12141838